Sunitinib malate

Sunitinib Malate is the orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation. This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells. It is grouped under the following drug class(es): Antineoplastic agents, Kinase inhibitors, Tyrosine Kinase Inhibitors and VEGF inhibitors. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Sutent and Sunitinib L-malate. Its PubChem CID is 6456015.